New radiation therapy shows promise for Hard-to-Treat tumors
NCT ID NCT05153772
First seen May 02, 2026 · Last updated May 08, 2026 · Updated 2 times
Summary
This study tests a new drug called 212Pb-DOTAMTATE that delivers radiation directly to neuroendocrine tumor cells. It includes 69 adults whose tumors have a specific marker (somatostatin receptor) and have worsened after standard treatments. The goal is to see if the drug can shrink tumors and control the disease safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas, 77042, United States
-
Louisiana State University (LSU) Health Sciences Center - New Orleans
Metairie, Louisiana, 70006, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Rocky Mountain Cancer Center
Denver, Colorado, 80218, United States
Conditions
Explore the condition pages connected to this study.